Brainsway Ltd

(NASDAQ:BWAY)

Latest On Brainsway Ltd (BWAY):

Date/Time Type Description Signal Details
2023-05-23 08:01 ESTNewsBrainsWay appoints CFON/A
2023-05-17 13:20 ESTNewsBrainsway GAAP EPS of -$0.07 beats by $0.04, revenue of $6.6M beats by $0.2MN/A
2023-03-15 22:33 ESTNewsBrainsway GAAP EPS of -$0.12 beats by $0.01, revenue of $6.03M misses by $0.27MN/A
2023-02-13 16:09 ESTNewsBrainsWay appoints CEON/A
2023-01-10 19:03 ESTNewsBrainsWay resolves unfair competition litigation with NeuroneticsN/A
2022-11-17 00:06 ESTNewsBrainsWay stock plummets 29% as Q3 loss widens, revenue fallsN/A
2022-09-14 17:31 ESTNewsBrainsWay gets significant private insurance coverage from Cigna for OCD treatment Utilizing Deep TMSN/A
2022-08-30 00:21 ESTNewsBrainsWay adds 20% on FDA nod for depression therapyN/A
2022-08-10 11:26 ESTNewsBrainsway GAAP EPS of -$0.07 in-line, revenue of $8.01M misses by $0.41MN/A
2022-07-12 21:56 ESTNewsBrainsWay's Shares Look AttractiveN/A
2022-06-28 17:40 ESTNewsBrainsway announces insurance coverage by Israeli Ministry of HealthN/A
2022-05-11 17:49 ESTNewsBrainsway GAAP EPS of -$0.06 beats by $0.01, revenue of $8M beats by $0.6MN/A
2022-03-09 18:53 ESTNewsBrainsway GAAP EPS of -$0.04 beats by $0.02, revenue of $8.47M beats by $0.23MN/A
2022-02-01 04:09 ESTNewsBrainsWay gets local coverage determination for BrainsWay Deep TMS to treat OCDN/A
2022-01-21 22:22 ESTNewsBrainsWay's Competitive Advantage Is GrowingN/A
2021-08-19 00:18 ESTNewsBrainsWay shares climb 20% after FDA's Deep TMS system 510k clearanceN/A
2021-08-11 15:17 ESTNewsBrainsway EPS beats by $0.13, beats on revenueN/A
2021-07-22 17:41 ESTNewsBrainsWay: Still Undervalued (Still)N/A
2021-04-30 04:39 ESTNewsBrainsWay launches noninvasive treatment for smoking addictionN/A
2021-04-26 14:45 ESTNewsBrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatmentN/A
2021-03-25 08:12 ESTNewsBrainsway EPS beats by $0.03, beats on revenueN/A
2021-03-02 10:32 ESTAnalyst RatingThe Analyst Target Price has increased from $13.19 to $13.38.Buy
2021-02-23 08:55 ESTNewsBrainsWay readies ADS offeringN/A
2021-02-18 02:17 ESTAnalyst RatingThe Analyst Target Price has increased from $11.94 to $13.19.Buy
2021-01-28 10:11 ESTAnalyst RatingThe Analyst Target Price has increased from $11.19 to $11.94.Buy
2021-01-25 12:19 ESTNewsBrainsWay shares fall despite supply deal with Gaelan Medical for Deep TMSN/A
2020-12-24 17:54 ESTNewsBrainsway: Still UndervaluedN/A
2020-12-04 06:36 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 01:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 23:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-19 15:47 ESTAnalyst RatingThe Analyst Target Price has increased from $11.01 to $11.19.Buy
2020-11-19 08:55 ESTNewsBrainsway EPS beats by $0.02, beats on revenueN/A
2020-11-19 08:55 ESTNewsBrainsway +4% on Q3 beat, bottom-line up 66%N/A
2020-10-08 21:24 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:40 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:48 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:27 ESTFinancialsCompany financials have been released.Neutral
2020-08-26 05:12 ESTNewsBrainsway: Lockdowns Are Hiding Progress In The BusinessN/A
2020-08-25 00:28 ESTNewsFDA OKs BrainsWay TMS system for smoking addictionN/A
2020-08-15 15:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 19:31 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:53 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 03:32 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.26 to $11.01.Neutral
2020-08-12 07:51 ESTNewsBrainsway EPS beats by $0.09, beats on revenueN/A
2020-08-06 16:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-04 19:54 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 12:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 04:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 20:54 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 08:41 ESTFinancialsCompany financials have been released.Neutral

About Brainsway Ltd (BWAY):

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

See Advanced Chart

General

  • Name Brainsway Ltd
  • Symbol BWAY
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Full Time Employees 107
  • Fiscal Year EndDecember
  • IPO Date1999-10-06
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryInternet Software & Services (discontinued effective close of September 28, 2018)
  • Web URLhttp://www.brainsway.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 4.55
  • Price/Book (Most Recent Quarter) 6.87
  • Enterprise Value Revenue 5.84
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.05
  • Profit Margin -34%
  • Operating Margin -25%
  • Return on Assets -9%
  • Return on Equity -32%
  • Revenue 21.28 million
  • Earnings Per Share -$1.03
  • Revenue Per Share $2.07
  • Gross Profit 19.16 million
  • Quarterly Earnings Growth 1.4%
View More

Highlights

  • Market Capitalization 139.75 million
  • EBITDA -4924000
  • Analyst Target Price $13.38
  • Book Value Per Share $1.77
View More

Share Statistics

  • Shares Outstanding 15.88 million
  • Shares Float 6.26 million
  • % Held by Insiders 289%
  • % Held by Institutions 18.18%
  • Shares Short 30570
  • Shares Short Prior Month 5475
  • Short Ratio 0.24
View More

Technicals

  • Beta 0.64
  • 52 Week High $10.57
  • 52 Week Low $5.52
  • 50 Day Moving Average 8.74
  • 200 Day Moving Average 7.07
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Brainsway Ltd (BWAY) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Brainsway Ltd (BWAY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-18$N/A-$0.04-$0.0524.95%
2020-06-302020-08-12$4.82 million-$0.03-$0.1275%
2020-03-312020-06-24$4.16 million-$0.15-$0.152.15%
2019-12-312020-03-23$6.29 million-$0.10-$0.1213.04%
2019-09-302019-11-25$5.93 million-$0.12-$0.120%
2019-06-302019-08-26$5.7 million-$0.17-$0.13-30.77%
2019-03-312019-04-17$5.18 million-$0.11-$0.1421.43%

Brainsway Ltd (BWAY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A 1.04 million 1.8 million 1.81 million 1.91 million
Income Before Tax N/A -394000 -3.31 million -2.17 million -2.52 million
Selling General Administrative N/A 3 million 4.97 million 1.72 million 5.04 million
Gross Profit N/A 3.83 million 3.14 million 4.85 million 4.78 million
Ebit N/A 360000 -2.88 million -2.36 million -1.46 million
Operating Income N/A -215000 -3.62 million -1.99 million -2.18 million
Income Tax Expense 170000 N/A 130000 147000 113000
Total Revenue N/A 4.82 million 4.16 million 6.29 million 5.93 million
Cost of Revenue N/A 992000 1.02 million 1.44 million 1.15 million
Total Other Income Expense Net N/A N/A N/A -1.37 million -344000
Net Income From Continuing Operations N/A -571000 -3.44 million -2.32 million -2.63 million
Net Income Applicable to Common Shares -966000 N/A -3.44 million -2.32 million -2.63 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A -968000 N/A -396000 -1.22 million
Change to Liabilities -664000 N/A -428000 285000 -449000
Total Cash Flow from Investing Activities -646000 N/A -936000 -396000 -1.22 million
Net Borrowings -101000 N/A -110000 -123000 -104000
Total Cash Flow from Financial Activities N/A -111000 N/A -414000 -363000
Change to Operating Activities 673000 N/A 338000 -5000 322000
Change in Cash N/A -356000 N/A -2.07 million -3.67 million
Total Cash from Operating Activities -1.12 million 616000 -2.58 million -1.23 million -2.06 million
Depreciation N/A 575000 N/A 659000 711000
Other Cash Flow from Investing Activities -2000 N/A 10000 -22000 1.01 million
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A 270000 N/A -469000 -637000
Other Cash Flow from Financing Activities N/A N/A 42000 -291000 -259000
Change to Net Income 362000 N/A 128000 1.81 million 625000
Capital Expenditures N/A 965000 N/A 338000 1.19 million
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A 14.55 million N/A 14.52 million 14.59 million
Total Stockholder Equity N/A 20.64 million N/A 24.22 million 26.26 million
Other Current Liabilities 6.06 million 998000 N/A 714000 1.05 million
Total Assets N/A 35.2 million N/A 38.74 million 40.84 million
Common Stock 233000 233000 233000 233000 202000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -76.89 million -75.92 million -75.35 million -71.91 million -69.59 million
Other Liabilities 7.5 million 7.03 million 7.02 million 7.14 million 7.34 million
Other Assets 163000 161000 158000 168000 160000
Cash N/A 17.61 million N/A 21.67 million 23.74 million
Total Current Liabilities 6.97 million 7.53 million N/A 6.72 million 7.25 million
Other Stockholder Equity 1.46 million 1.23 million 1.9 million 2.25 million 1.97 million
Property, Plant & Equipment 10.14 million 10.85 million 10.14 million 9.74 million 10.07 million
Total Current Assets 24.08 million 24.18 million N/A 28.83 million 30.62 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 19.91 million 20.64 million 21.09 million 24.22 million 26.26 million
Short Term Investments N/A N/A N/A 221000 171000
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A 306000 N/A
Accounts Payable 911000 2.06 million N/A 1.32 million 1.56 million

Brainsway Ltd (BWAY) Chart:

Brainsway Ltd (BWAY) News:

Below you will find a list of latest news for Brainsway Ltd (BWAY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Brainsway Ltd (BWAY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest BWAY Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$5.115
Jun 13, 2022 7:59 PM EST100$5.115
Jun 13, 2022 7:59 PM EST100$5.115
Jun 13, 2022 7:59 PM EST100$5.115
Jun 13, 2022 7:59 PM EST100$5.105

Brainsway Ltd (BWAY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-246-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320004547/0001171843-20-004547-index.htm
2020-01-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1505065/000089843220000089/0000898432-20-000089-index.htm
2019-04-17424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1505065/000104746919002315/0001047469-19-002315-index.htm
2019-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000110465919021835/0001104659-19-021835-index.htm
2019-04-22S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1505065/000110465919022864/0001104659-19-022864-index.htm
2019-04-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319002535/0001171843-19-002535-index.htm
2019-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319003556/0001171843-19-003556-index.htm
2019-05-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319003580/0001171843-19-003580-index.htm
2019-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319003660/0001171843-19-003660-index.htm
2019-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319004017/0001171843-19-004017-index.htm
2019-06-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319004210/0001171843-19-004210-index.htm
2019-07-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319004634/0001171843-19-004634-index.htm
2019-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319005483/0001171843-19-005483-index.htm
2019-08-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319005645/0001171843-19-005645-index.htm
2019-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319005939/0001171843-19-005939-index.htm
2019-09-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319006000/0001171843-19-006000-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319006472/0001171843-19-006472-index.htm
2019-10-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319006585/0001171843-19-006585-index.htm
2019-10-316-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319007035/0001171843-19-007035-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319007548/0001171843-19-007548-index.htm
2019-11-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319007758/0001171843-19-007758-index.htm
2019-11-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319007764/0001171843-19-007764-index.htm
2019-11-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319007768/0001171843-19-007768-index.htm
2019-12-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319007879/0001171843-19-007879-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184319008022/0001171843-19-008022-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320000217/0001171843-20-000217-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320000753/0001171843-20-000753-index.htm
2020-02-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320000808/0001171843-20-000808-index.htm
2020-02-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320000815/0001171843-20-000815-index.htm
2020-03-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320001466/0001171843-20-001466-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320001628/0001171843-20-001628-index.htm
2020-03-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320001902/0001171843-20-001902-index.htm
2020-04-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320002556/0001171843-20-002556-index.htm
2020-05-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320003358/0001171843-20-003358-index.htm
2020-05-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320003859/0001171843-20-003859-index.htm
2020-06-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320004253/0001171843-20-004253-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320004517/0001171843-20-004517-index.htm
2020-06-246-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320004547/0001171843-20-004547-index.htm
2020-07-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320005321/0001171843-20-005321-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320005839/0001171843-20-005839-index.htm
2020-08-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320006059/0001171843-20-006059-index.htm
2020-09-04F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1505065/000117184320006278/0001171843-20-006278-index.htm
2020-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1505065/000117184320007536/0001171843-20-007536-index.htm
2019-05-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1505065/000117891319001327/0001178913-19-001327-index.htm
2020-02-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1505065/000117891320000579/0001178913-20-000579-index.htm
2020-03-2320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1505065/000121390020007056/0001213900-20-007056-index.htm
2019-08-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1505065/000149315219013024/0001493152-19-013024-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1505065/000149315220002365/0001493152-20-002365-index.htm
2020-10-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1505065/999999999520002886/9999999995-20-002886-index.htm